Gilead Sciences Inc at Goldman Sachs Global Healthcare Conference Transcript
Thanks so much for joining us. Really pleased to have the Gilead team here with us. We have Dan O'Day, CEO; and Merdad Parsey, CMO.
With that, Dan, I'll turn it over to you for any opening comments, and then we can jump into Q&A.
' -
Sure, sure. Well, first of all, thanks for coming here and being with us today. I'm delighted to be here with Merdad. Look, I think this is an exciting time at Gilead for us right now. We are coming off of also, I think, a strong ASCO in terms of the entirety of data that we have. I would just say that -- and we'll get into the questions. But I think what the team at Gilead has built up over the past couple of years has really been impressive, and what I mean by that is the pipeline has increased by more than 50%.
That number, I think, really underestimates what the potential of the pipeline is because the whole nature of the pipeline has changed accordingly. Our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
